Epidemiologists have unexpectedly found that African Americans had a higher rate of recurrence following prostate cancer surgery than did whites, regardless of whether or not patients received surgery at hospitals or by surgeons who performed a high number of such operations.
Researchers at the University of Michigan Comprehensive Cancer Center have identified a new imaging technique that can measure the effectiveness of treatment for prostate cancer that has spread to the bones. The technique involves measuring diffusion of water within tumors.
A new study in Psychophysiology confirms a surprising fact ? men who have undergone chemical castration for conditions such as prostate cancer experience hot flashes similar to those experienced by menopausal women.
Among men who have received similar treatments for prostate cancer, those with less education ? particularly those who did not graduate from high school ? experience a significant drop in their quality of life after treatment compared with men who have more education, according to a study led by researchers at the San Francisco VA Medical Center (SFVAMC).
A detectable level of prostate-specific antigen (PSA) is the first indicator of recurrent prostate cancer after radical prostatectomy. In a new Mayo Clinic study, the concept of PSA doubling time (DT) is found to be a reliable tool to distinguish which patients have prolonged innocuous PSA levels after therapy from those who are at great risk for disease recurrence and death from prostate cancer.
A senior UK oncologist Chris Hamilton admitted that thousands of men with prostate cancer are being given unnecessary and potentially harmful drug treatment to clear hospital waiting lists in UK.
Cell Genesys, Inc. (Nasdaq: CEGE) announced final, updated results from its second multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer which evaluated escalating doses of the immunotherapy in 80 patients with metastatic hormone-refractory prostate cancer (HRPC).
A study led by researchers at the Keck School of Medicine of the University of Southern California (USC) and Harvard Medical School has identified seven genetic risk factors?DNA sequences carried by some people but not others?that predict risk for prostate cancer.
Dendreon Corporation (Nasdaq: DNDN) announced that the U.S. Food and Drug Administration’s (FDA) Office of Cellular, Tissue and Gene Therapies Advisory Committee recommended to the FDA that there is substantial evidence of efficacy and safety of PROVENGE (sipuleucel-T) for the treatment of patients with asymptomatic, metastatic, androgen-independent (also known as hormone refractory) prostate cancer.
Two Rutgers College of Nursing faculty members are conducting a study to develop and test a targeted intervention to reduce symptoms and improve the quality of life of patients undergoing prostate cancer treatment.